Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Cash from Investing Activities data on record, last reported at $57.1 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 110.53% year-over-year to $57.1 million; the TTM value through Dec 2025 reached $173.9 million, up 130.25%, while the annual FY2025 figure was $173.9 million, 130.25% up from the prior year.
  • Cash from Investing Activities reached $57.1 million in Q4 2025 per CRNX's latest filing, down from $164.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $164.8 million in Q3 2025 and bottomed at -$542.1 million in Q4 2024.
  • Average Cash from Investing Activities over 5 years is -$41.6 million, with a median of $3.6 million recorded in 2022.
  • The widest YoY moves for Cash from Investing Activities: up 699.93% in 2025, down 27919.09% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$101.8 million in 2021, then skyrocketed by 136.2% to $36.9 million in 2022, then plummeted by 336.91% to -$87.3 million in 2023, then crashed by 520.89% to -$542.1 million in 2024, then surged by 110.53% to $57.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $57.1 million in Q4 2025, $164.8 million in Q3 2025, and $38.0 million in Q2 2025.